A HIV Vaccine Proves Elusive Again As J&J Study Fails
Virus Continues To Evade Vaccine Developers
Another vaccine failure shows that HIV’s ability to “attack, hijack and evade” the human immune system is still outwitting researchers, but J&J will continue with Phase III study of a related vaccine.
You may also be interested in...
The Bill Gates Foundation-backed partnership with IAVI could bring a HIV vaccine a step closer, but generating the right antibody response has defeated many previous attempts.
GSK looks to Cabenuva to get ahead in the long-acting HIV therapy and PrEP market, but Gilead will not relinquish its lead easily.
Chief scientific officer Paul Stoffels will retire at the end of the year at the same time CEO Alex Gorsky will hand over the top leadership role to Joaquin Duato; no successor has been named.